Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Breast Cancer × eribulin × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Sarcoma 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Inflammatory Breast Neoplasms 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER-2 Positive Breast Cancer 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

sacituzumab govitecan 1 eribulin 1 balixafortide 1 Taxes 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04826016 2023-03-20

POLTER

MedSIR

Phase 1/2 Withdrawn

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡